BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma D, Liu X, Liu J, Li M, Chen L, Gao M, Xu W, Yang Y. Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice. Brain Res 2019;1714:126-32. [PMID: 30826352 DOI: 10.1016/j.brainres.2019.02.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Rhee EJ. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Endocrinol Metab (Seoul) 2022;37:415-29. [PMID: 35798548 DOI: 10.3803/EnM.2022.304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Manfready RA, Forsyth CB, Voigt RM, Hall DA, Goetz CG, Keshavarzian A. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep 2022. [PMID: 35633466 DOI: 10.1007/s11910-022-01196-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cheng D, Yang S, Zhao X, Wang G. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug Des Devel Ther 2022;16:665-84. [PMID: 35340338 DOI: 10.2147/DDDT.S348055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Liu M, Jiao Q, Du X, Bi M, Chen X, Jiang H. Potential Crosstalk Between Parkinson's Disease and Energy Metabolism. Aging Dis 2021;12:2003-15. [PMID: 34881082 DOI: 10.14336/AD.2021.0422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Labandeira CM, Fraga-Bau A, Arias Ron D, Muñoz A, Alonso-Losada G, Koukoulis A, Romero-Lopez J, Rodriguez-Perez AI. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists. Front Neuroendocrinol 2021;62:100914. [PMID: 33845041 DOI: 10.1016/j.yfrne.2021.100914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
7 Lu Y, Mao J, Han X, Zhang W, Li Y, Liu Y, Li Q. Downregulated hypoxia-inducible factor 1α improves myoblast differentiation under hypoxic condition in mouse genioglossus. Mol Cell Biochem 2021;476:1351-64. [PMID: 33389500 DOI: 10.1007/s11010-020-03995-1] [Reference Citation Analysis]
8 Zhang H, Chu Y, Zheng H, Wang J, Song B, Sun Y. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging (Albany NY) 2020;13:525-36. [PMID: 33298623 DOI: 10.18632/aging.202162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Bulgakova, Romanchuk, Treneva. Glucagon-like Peptide 1, Brain, Neurodegenerative Diseases: A Modern View. BSP 2020;6:153-172. [DOI: 10.33619/2414-2948/53/19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Grieco M, Giorgi A, Gentile MC, d'Erme M, Morano S, Maras B, Filardi T. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci 2019;13:1112. [PMID: 31680842 DOI: 10.3389/fnins.2019.01112] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 23.7] [Reference Citation Analysis]